Helicobacter pylori: Eradication Pharmacotherapy
Core concept: Eradication requires an effective antimicrobial regimen plus acid suppression selected with resistance risk and previous antibiotic exposure in mind (Chey et al., 2024).
Key clinical distinction: Symptom relief is not proof of bacterial eradication; correctly timed post-treatment testing is necessary (Chey et al., 2024).
Prescribing priority: Use a test that detects active infection, select therapy around susceptibility and prior antibiotic exposure, and document eradication in every treated adult. Uncomplicated acid suppression alone is not H. pylori treatment (Chey et al., 2024; Chaudhry & Corder, 2026).
Who to Evaluate and How to Test
H. pylori is associated with peptic ulcer disease, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer. Testing and treatment are appropriate for current or previous peptic ulcer disease and additional guideline-specified high-risk groups. Dyspepsia in a younger adult without alarm features may be evaluated with a noninvasive test-and-treat strategy; patients with alarm findings, selected cancer risks, or another endoscopy indication should undergo appropriate diagnostic assessment (Chey et al., 2024).
Urea breath testing and stool antigen testing identify active infection and are useful for both initial detection and post-treatment confirmation. Serology may reflect remote exposure and cannot establish cure. PPIs, potassium-competitive acid blockers (PCABs), bismuth and antibiotics can suppress organism detection and produce false-negative tests; consider medication exposure when interpreting a negative result (Chey et al., 2024; Chaudhry & Corder, 2026).
Empiric Eradication in Adults: The 2024 ACG Pathway
When antibiotic susceptibility is unknown, 14-day optimized bismuth quadruple therapy is the preferred treatment-naïve regimen. A rifabutin-based triple regimen or vonoprazan-amoxicillin dual therapy is an empiric alternative in adults without penicillin allergy. Avoid empiric clarithromycin- or levofloxacin-containing regimens when susceptibility is not proven. This represents a meaningful change from the 2017 guideline incorporated into some older textbook tables (Chey et al., 2024).
| Regimen | Adult doses and duration | Place in therapy / constraints |
|---|---|---|
| Optimized bismuth quadruple (separate components) | PPI twice daily + bismuth subcitrate 120–300 mg or subsalicylate 300–524 mg four times daily + tetracycline 500 mg four times daily + metronidazole 500 mg three or four times daily; 14 days. | Preferred empiric choice with unknown susceptibility, including many penicillin-allergic patients. Doxycycline is not a recommended tetracycline substitute. |
| Rifabutin triple (Talicia coformulation) | Four capsules orally three times daily with food, at least 4 hours between doses, for 14 days; each four-capsule dose = omeprazole 40 mg + amoxicillin 1,000 mg + rifabutin 50 mg. | Empiric alternative if no penicillin allergy, including selected rescue settings; important interaction, liver, marrow and pregnancy considerations. |
| Vonoprazan-amoxicillin dual (Voquezna Dual Pak) | Vonoprazan 20 mg orally twice daily + amoxicillin 1,000 mg orally three times daily for 14 days. | Alternative empiric regimen when no penicillin allergy; check renal/hepatic exclusions and interacting medications. |
| Clarithromycin- or levofloxacin-based salvage | Dose and component selection depend on confirmed susceptibility and clinical history. | Reserve for proven susceptibility; do not use merely because a prior empiric course failed. |
This original summary reflects the ACG guideline and individual product labels; it is not a substitution for label-based prescribing in pregnancy, hepatic or renal impairment, or complex polypharmacy (Chey et al., 2024; Phathom Pharmaceuticals Inc., 2025; RedHill Biopharma Ltd., 2025).
Brand-Pack Dosing Is Not Equivalent to Optimized Guideline Dosing
The FDA-labeled Pylera regimen is three capsules four times daily after meals and at bedtime plus omeprazole 20 mg twice daily for 10 days. Each capsule contains bismuth subcitrate potassium 140 mg, metronidazole 125 mg and tetracycline 125 mg. Thus each three-capsule dose contains 375 mg metronidazole and 375 mg tetracycline, which is not the same as a 14-day optimized bismuth regimen containing tetracycline 500 mg four times daily and metronidazole 500 mg three or four times daily. Do not equate the Pylera 10-day labeled course with the 14-day optimized ACG regimen, or convert between different bismuth salts by milligram amount alone (Chey et al., 2024; H2-Pharma, LLC, 2026).
Prescribing Safeguards for Co-Packaged Eradication Regimens
| Product | Indication-specific schedule | Exclude or reconcile before prescribing |
|---|---|---|
| Pylera plus omeprazole | 3 Pylera capsules after each meal and at bedtime (4 times/day), PLUS omeprazole 20 mg twice daily, for 10 labeled days. | Not the optimized ACG 14-day regimen; severe renal impairment, pregnancy, recent disulfiram, Cockayne syndrome, alcohol during and for 3 days after therapy; pill esophagitis prevention. |
| Talicia | 4 combination capsules with food, 3 times/day at least 4 hours apart for 14 days. Do not crush. | Beta-lactam/rifamycin/PPI hypersensitivity, CYP interactions, pregnancy/contraceptive implications, rifabutin-related cytopenia/uveitis, medication access. |
| Voquezna Dual Pak | Vonoprazan 20 mg twice/day PLUS amoxicillin 1,000 mg 3 times/day for 14 days. | Penicillin allergy, concomitant rilpivirine (contraindicated), renal/hepatic restrictions and amoxicillin interactions; dual is not clarithromycin triple pack. |
A medication reconciliation must distinguish true anaphylactic penicillin allergy from an unverified historical intolerance. For persistent infection, record each past antimicrobial and duration before salvage selection. Neither a 10-day branded pack nor a 14-day dual pack should be represented as universally interchangeable with 14-day optimized bismuth quadruple treatment (Chey et al., 2024; H2-Pharma, LLC, 2026; Phathom Pharmaceuticals Inc., 2025; RedHill Biopharma Ltd., 2025).
Selection Must Reflect Prior Treatment and Resistance
| Patient history | Preferred next decision | Reasoning |
|---|---|---|
| Treatment-naïve, antibiotic susceptibility unknown | Select 14-day optimized bismuth quadruple therapy; consider alternatives if the patient is not penicillin-allergic. | Empiric clarithromycin triple therapy has poor performance with resistance. |
| Prior PPI–clarithromycin triple therapy failure | Use optimized bismuth quadruple therapy if not previously administered. | Avoid reusing a regimen likely compromised by resistance. |
| Prior optimized bismuth quadruple therapy failure | Rifabutin-based triple therapy is a suggested empiric alternative if no penicillin allergy; evaluate susceptibility and specialist options. | Repeating optimized bismuth quadruple therapy is not the default salvage strategy. |
| Reported penicillin allergy | Assess allergy history; optimized bismuth quadruple is generally an option. Consider formal allergy evaluation when treatment options are restricted. | An unverified penicillin allergy can unnecessarily exclude effective regimens. |
| Multiple regimen failures | Review complete antibiotic exposure and adherence; arrange GI/infectious-disease input and susceptibility-guided therapy when feasible. | Persistence demands a new evidence-based strategy, not serial empiric recycling. |
Medication Safety, Interactions, and Counseling
- Tetracycline: review pregnancy status, renal impairment, and concurrent dairy, calcium, iron, zinc, antacids, or other cations that reduce absorption; counsel on photosensitivity and fluid intake to prevent pill esophagitis. Do not substitute doxycycline into optimized therapy.
- Pylera-specific exclusions: The combination product is contraindicated during pregnancy, in severe renal impairment, in patients with Cockayne syndrome, and when disulfiram was used within the preceding 2 weeks. Review the precise current package label before selecting it (H2-Pharma, LLC, 2026).
- Metronidazole: review clinically relevant interactions and adverse effects. Alcohol avoidance is explicitly required by the Pylera label during therapy and for at least 3 days afterward; disulfiram, neurologic toxicity, severe liver disease, and the label’s animal carcinogenicity warning also warrant review.
- Bismuth: transient black tongue and stool are possible. Distinguish medication-related discoloration from gastrointestinal bleeding. Consider salicylate exposure when using subsalicylate and evaluate renal disease.
- Rifabutin regimens: verify hypersensitivity to rifamycins or penicillins, interacting antivirals/antifungals, hormonal contraceptive counseling, hepatic status, and possible hematologic toxicity. Use the exact Talicia schedule if that product is prescribed.
- Vonoprazan dual therapy: verify penicillin allergy, renal/hepatic status and contraindicated rilpivirine-containing therapy; its amoxicillin schedule remains three times daily even though vonoprazan is twice daily.
- Use a written administration schedule and shared decision-making. Check the prescribed dose, interval, formulation, interactions, adherence barriers, and a documented test-of-cure plan before concluding that treatment has succeeded.
Test of Cure: Completion Is a Documented Endpoint
Confirm eradication in every treated adult, regardless of symptom improvement, using urea breath testing, stool antigen testing, or biopsy-based testing if another endoscopy is clinically indicated. Perform testing at least 4 weeks after the last antibiotic/bismuth dose and withhold PPIs or PCABs for at least 2 weeks before testing. H2RAs or antacids may be used temporarily when clinically appropriate. Serology cannot confirm eradication (Chey et al., 2024).
At follow-up, reconcile the exact regimen, dates, adherence, adverse events, prior macrolide/quinolone exposure, and results. Ongoing dyspepsia despite confirmed cure calls for a new differential diagnosis rather than automatic repeat antibiotics (Chey et al., 2024; Chaudhry & Corder, 2026).
Special Clinical Boundaries
Children and adolescents should not automatically follow this adult algorithm. The joint 2024 ESPGHAN/NASPGHAN guideline emphasizes indications for pediatric endoscopic assessment, susceptibility-guided therapy, and age-appropriate regimens (Homan et al., 2024). Pregnancy or breastfeeding, significant hepatic or renal impairment, complex drug interactions, or a history of multiple failures requires individualized specialist- and label-informed selection.
Bleeding, progressive dysphagia, unexplained weight loss, persistent vomiting, or anemia requires evaluation beyond H. pylori eradication. Suspected perforation or peritoneal signs are an acute-care emergency, not an indication for empiric outpatient eradication therapy (Chaudhry & Corder, 2026).
After Treatment Failure, Reconstruct the Antibiotic History Before Prescribing
Persistent H. pylori after treatment is not a reason to repeat the same empirical antibiotics. First verify that eradication failure was established by an appropriate active-infection test, that the medication was taken correctly, and that antibiotic exposure and adverse effects are documented. If a patient has never completed optimized 14-day bismuth quadruple therapy (BQT), that is the preferred empiric approach when susceptibility is unknown. If optimized BQT was already completed, 14-day rifabutin-based triple therapy is a suitable empiric alternative in a patient without penicillin allergy. Do not use empiric clarithromycin- or levofloxacin-containing rescue regimens without demonstrated susceptibility (Chey et al., 2024).
A reported penicillin allergy requires clarification of reaction phenotype and severity rather than immediate selection of a less effective regimen. Referral for structured allergy evaluation can expand treatment choices when appropriate. If prior antibiotics, cost, availability or treatment intolerance make empiric selection difficult, susceptibility testing and specialist consultation may become decisive (Chey et al., 2024).
Testing, Washout and Cure Confirmation Are Separate Checkpoints
Confirm active infection using an appropriate test for the clinical question. For test of cure, schedule urea breath testing or stool antigen testing at least 4 weeks after completion of antibiotics, and withhold PPIs or P-CABs for 2 weeks beforehand when safe; bismuth and antibiotics also need an adequate washout. When acid suppression is needed during the PPI washout, follow the performing laboratory’s test-specific instructions for any H2RA or antacid use; do not assume washout rules are interchangeable. Serology cannot establish eradication because antibodies may remain positive after successful therapy. Recurrent ulceration or alarm findings warrant individualized evaluation of whether endoscopy is indicated; recurrence alone does not mandate endoscopy for every patient (Chey et al., 2024).
At the prescribing visit, write a single comprehensible day-by-day administration schedule, check medication reconciliation for acid-dependent interactions and antiplatelet therapy, and document the exact planned test-of-cure date. Eradication is established by the post-treatment test, not by completion of the last antibiotic dose or improvement in dyspepsia alone (Chey et al., 2024).
Decision pathway: Treatment history
| Treatment history | Next action | Common error prevented |
|---|---|---|
| Untreated; susceptibility unknown | Optimized 14-day bismuth quadruple therapy; selected alternatives according to allergy and access. | Empiric clarithromycin triple therapy despite resistance concern. |
| Persistent infection; no prior optimized BQT | Use optimized BQT, accounting for actual previous drugs and adherence. | Repeating unsuccessful clarithromycin empirically. |
| Persistent after completed optimized BQT | Consider 14-day rifabutin triple if no penicillin allergy; specialist/susceptibility review. | Cycling the same antibiotics without evaluating resistance. |
| Reported penicillin allergy | Clarify reaction and consider allergy evaluation if choices constrained. | Assuming all labels of penicillin allergy represent anaphylaxis. |
| Symptom improvement after therapy | Document active-infection test of cure after correct washout. | Using serology or symptom resolution as proof of eradication. |
Applied Clinical Case and Prescribing Rationale
Scenario: A 55-year-old completed an unknown “triple therapy” last year, has persistent positive stool antigen and says amoxicillin caused nausea in childhood. They ask for the same regimen again. What information changes the plan?
Reasoned response: Obtain pharmacy/prior-treatment records, characterize the adverse reaction rather than equating isolated nausea with immediate allergy, review adherence, and confirm the timing/quality of the positive test. If optimized BQT was never used, it is a guideline-favored empiric pathway; prior optimized BQT failure instead changes the salvage choice. Assign a future test-of-cure with required washouts before considering treatment complete (Chey et al., 2024).
High-Yield Distinctions
High-yield point
Patient A has confirmed active H. pylori, no penicillin allergy, and no prior eradication. Without susceptibility information, choose an optimized 14-day bismuth quadruple regimen, not routine PPI–clarithromycin triple therapy. Patient B completed therapy and feels better; symptoms alone cannot establish cure. Patient C has persistent infection after optimized bismuth quadruple therapy; evaluate prior adherence and antibiotics, and consider a different supported salvage regimen instead of repeating the same course (Chey et al., 2024).
Key clinical distinction: Eradication requires effective antimicrobials plus acid suppression, resistance-aware selection, and an objective test of cure. Symptomatic relief is not a surrogate for microbial clearance.
Related YourDNP Resources
Pharmacology learning hub | Peptic Ulcer Disease | GERD Pharmacotherapy
Content last reviewed:
References
Chaudhry, F., & Corder, M. M. (2026). Peptic ulcer disease. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 19). McGraw Hill.
Chey, W. D., Howden, C. W., Moss, S. F., Morgan, D. R., Greer, K. B., Grover, S., & Shah, S. C. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection. American Journal of Gastroenterology, 119(9), 1730–1753. https://doi.org/10.14309/ajg.0000000000002968
H2-Pharma, LLC. (2026, January 16). Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c50626a2-5969-490b-a88a-a4ee45e79615
Homan, M., Jones, N. L., Bontems, P., Carroll, M. W., Czinn, S. J., Gold, B. D., Goodman, K., Harris, P. R., Jerris, R., Kalach, N., Kori, M., Megraud, F., Rowland, M., & Tavares, M. (2024). Updated joint ESPGHAN/NASPGHAN guidelines for management of Helicobacter pylori infection in children and adolescents (2023). Journal of Pediatric Gastroenterology and Nutrition, 79(3), 758–785. https://doi.org/10.1002/jpn3.12314
Phathom Pharmaceuticals Inc. (2025, December 18). Voquezna Dual Pak and Voquezna Triple Pak [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cb2ee04-8581-46c8-a781-7be170ab5c86
RedHill Biopharma Ltd. (2025, December 23). Talicia (omeprazole magnesium, amoxicillin, and rifabutin) delayed-release capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68c4e9dc-dbcf-4151-b6f7-5e4b9922b76f